SCHEMBL29635641

SCHEMBL29635641

Fc1ccccc1OCC(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
USP2 O75604 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
THRB P10828 1/20 0.45
G6PD P11413 1/20 0.45
ALOX15 P16050 1/20 0.45
CASP1 P29466 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10499330 1.00 L3MBTL1 (0.48) L3MBTL1TDP1MEN1KMT2AKDM4E
SCHEMBL28697944 0.83 L3MBTL1 (0.42) L3MBTL1TDP1MEN1KMT2AKDM4E
SCHEMBL22508538 0.81 L3MBTL1 (0.52) L3MBTL1TDP1MEN1KMT2AKDM4E
SCHEMBL24180130 0.80 ALDH1A1 (0.48) L3MBTL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL13696491 0.80 MAPT (0.40) L3MBTL1TDP1MEN1KMT2AKDM4E
SCHEMBL28935348 0.79 MAPT (0.47) L3MBTL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL3341627 0.78 KDM4E (0.67) L3MBTL1TDP1MEN1KMT2AKDM4E
SCHEMBL16252782 0.78 L3MBTL1 (0.49) L3MBTL1TDP1MEN1KMT2AKDM4E
SCHEMBL18297649 0.77 ALDH1A1 (0.38) L3MBTL1TDP1MEN1KMT2AKDM4E
SCHEMBL1154555 0.77 MAPT (0.38) L3MBTL1MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2025-06-24 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US disclosed
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2022-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNT, NQO1 L3MBTL1 3643/4885TDP1 4076/4885MEN1 438/4885
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NNT L3MBTL1 3102/4885TDP1 3705/4885MEN1 491/4885
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 L3MBTL1 2990/4885TDP1 3665/4885MEN1 473/4885
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 L3MBTL1 3563/4885TDP1 3947/4885MEN1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.